CoChat

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and associated precancerous lesions in an event-triggered interim analysis of the phase III randomised, double-blind, controlled PApilloma TRIal against Cancer In young Adults (PATRICIA). We now assess the vaccine efficacy in the final event-driven analysis.Methods Women (15-25 years) were vaccinated at months 0, 1, and 6. Analyses were done in the according-to-protocol cohort for efficacy (ATP-E; vaccine, n=8093; control, n=8069), total vaccinated cohort (TVC, included all women receiving at least one vaccine dose, regardless of their baseline HPV status; represents the general population, including those who are sexually active; vaccine, n=9319; control, n=9325), and TVC-naive (no evidence of oncogenic HPV infection at baseline; represents women before sexual debut; vaccine, n=5822; control, n=5819). The primary endpoint was to assess vaccine efficacy against cervical intraepithelial neoplasia 2+ (CIN2+) that was associated with HPV-16 or HPV-18 in women who were seronegative at baseline, and DNA negative at baseline and month 6 for the corresponding type (ATP-E). This trial is registered with ClinicalTrials.gov, number NCT00122681.Findings Mean follow-up was 34.9 months (SD 6.4) after the third dose. Vaccine efficacy against CIN2+ associated with HPV-16/18 was 92.9% (96.1% CI 79.9-98.3) in the primary analysis and 98.1% (88.4-100) in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types (ATP-E cohort). Vaccine efficacy against CIN2+ irrespective of HPV DNA in lesions was 30.4% (16.4-42.1) in the TVC and 70.2% (54.7-80.9) in the TVC-naive. Corresponding values against CIN3+ were 33.4% (9.1-51.5) in the TVC and 87.0% (54.9-97.7) in the TVC-naive. Vaccine efficacy against CIN2+ associated with 12 non-vaccine oncogenic types was 54.0% (34.0-68.4; ATP-E). Individual cross-protection against CIN2+ associated with HPV-31, HPV-33, and HPV-45 was seen in the TVC.Interpretation The HPV-16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.Funding GlaxoSmithKline Biologicals.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)61248-4

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 1,655

Metadata

Authors
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., Bosch, F., Jenkins, D., Hardt, K., Zahaf, T., Descamps, D., Struyf, F., Lehtinen, M., & Dubin, G.
Affiliations
  • University of Helsinki (FI)
  • Universidade Federal do Rio Grande do Sul (BR)
  • Mexican Social Security Institute (MX)
  • National Taiwan University (TW)
  • Väestöliitto (FI)
  • Manchester Academic Health Science Centre (GB)
  • Universidade Estadual de Campinas (UNICAMP) (BR)
  • Chulalongkorn University (TH)
  • Philippine General Hospital (PH)
  • Royal Women's Hospital (AU)
  • Queen Mary University of London (GB)
  • University of Alberta (CA)
  • Universitätsklinikum Würzburg (DE)
  • Universitair Ziekenhuis Leuven (BE)
  • University of York (GB)
  • GlaxoSmithKline (Belgium) (BE)
  • University of Tampere (FI)
  • GlaxoSmithKline (United States) (US)
Corresponding author
Paavonen, J
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-07
Volume
374
Issue
9686
Pages
301-314
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2136236728
Cited by
1,655
References
33
Citations by year
2026: 32 · 2025: 41 · 2024: 34 · 2023: 45 · 2022: 66 · 2021: 55 · 2020: 68 · 2019: 72 · 2018: 57 · 2017: 100 · 2016: 96 · 2015: 132 · 2014: 158 · 2013: 151 · 2012: 185
FWCI
121.52
Type
journal article
Language
en
Update notices
erratum (2010-09-25)
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders
GlaxoSmithKline
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Surgery › Genital Health and Disease
Keywords
HPV-16/18 AS04-adjuvanted vaccine, HPV vaccine efficacy, HPV16, HPV 18, high-risk HPV genotypes, cervical precancerous lesions, young women, seronegative women, vaccine safety, HPV prevention
MeSH terms
Adolescent, Adult, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Double-Blind Method, Female, Humans, Neoplasm Staging, Precancerous Conditions, Safety, Sexual Behavior, Vaginal Smears, Treatment Outcome, Papillomavirus Infections, Mass Vaccination, Human papillomavirus 18, Human papillomavirus 16, Papillomavirus Vaccines, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. https://app.cochat.ai/papers/10.1016/s0140-6736(09)61248-4
The paper
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., . . . Dubin, G. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet. https://doi.org/10.1016/s0140-6736(09)61248-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.